Abeona Therapeutics (NASDAQ:ABEO) Coverage Initiated at Oppenheimer

Research analysts at Oppenheimer began coverage on shares of Abeona Therapeutics (NASDAQ:ABEO) in a research note issued to investors on Wednesday, Marketbeat.com reports. The firm set an “outperform” rating and a $16.00 price target on the biopharmaceutical company’s stock. Oppenheimer’s target price indicates a potential upside of 201.89% from the company’s current price.

A number of other equities analysts have also issued reports on the company. HC Wainwright reaffirmed a “buy” rating and issued a $15.00 target price on shares of Abeona Therapeutics in a research report on Wednesday, February 19th. StockNews.com lowered shares of Abeona Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday, February 22nd. One research analyst has rated the stock with a sell rating and four have issued a buy rating to the company. According to MarketBeat.com, Abeona Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $17.50.

Abeona Therapeutics Stock Up 0.8 %

Shares of NASDAQ ABEO opened at $5.30 on Wednesday. The firm has a market cap of $230.40 million, a price-to-earnings ratio of -1.97 and a beta of 1.79. Abeona Therapeutics has a 1 year low of $3.05 and a 1 year high of $8.87. The company has a debt-to-equity ratio of 0.31, a quick ratio of 6.12 and a current ratio of 6.12. The stock’s 50-day simple moving average is $5.57 and its 200-day simple moving average is $5.85.

Institutional Trading of Abeona Therapeutics

Institutional investors and hedge funds have recently bought and sold shares of the company. Twinbeech Capital LP bought a new stake in shares of Abeona Therapeutics in the 4th quarter valued at approximately $58,000. Squarepoint Ops LLC acquired a new position in Abeona Therapeutics in the fourth quarter worth $67,000. Jane Street Group LLC bought a new stake in Abeona Therapeutics during the third quarter valued at $84,000. Oxford Asset Management LLP acquired a new stake in shares of Abeona Therapeutics during the fourth quarter worth $118,000. Finally, Charles Schwab Investment Management Inc. bought a new position in shares of Abeona Therapeutics in the 3rd quarter worth about $151,000. Institutional investors and hedge funds own 80.56% of the company’s stock.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.